Experience DIA At The 19th Annual EuroMeeting

The DIA is hosting its 19th Annual EuroMeeting, March 26-28, 2007,
in Vienna, Austria, a one-of-a-kind annual event that brings together
professionals from the biopharmaceutical industry, contract service
organisations, academic research centres and regulatory agencies.

As the largest industry event in Europe, the 19th
Annual EuroMeeting provides the foremost neutral forum for the
discussion of a variety of multi-disciplinary topics--from regulatory
compliance to information technology to project management and GCP.
Europe's annual flagship is global in scope, attracts more than 2,600
attendees from over 50 countries, offers more than 130 timely and
relevant session topics, continuing education, networking
opportunities and access to a sold-out exhibit hall with 230-plus
exhibitors. In addition, representatives from EMEA, FDA and regulatory
agencies throughout Europe will be present.

"More than 400 speakers will discuss best practices and strategies
for the research and development of new clinical entities,
biotechnology-derived compounds, vaccines and generics," said Christa
Wirthumer-Hoche, EuroMeeting Co-Chair. "We are confident that this
year's meeting will provide attendees with the latest information and
opportunities unavailable at other industry events."

Featured tracks will include:

-- Patient Organisations' Involvement in Medicine Development

-- Intellectual Property Rights and Related Issues (Half Track
Tuesday)

-- Quality and Compliance

-- Clinical Quality Management, GCP and Inspections

-- Medicines for Children

-- Biosimilars - Current Status and Latest Developments (Half
Track)

Visit www.diahome.org for a complete list of tracks and sessions.

"In Europe, drug development is becoming more complex. Similarly,
the development of pharmaceutical compounds and their regulations is
constantly being challenged," said Gerd Bode, EuroMeeting Co-Chair.
"We are hopeful that by stimulating the research and development of
innovative medicines, we can improve R&D processes, design new
paradigms and remove obstacles. The EuroMeeting will provide the
latest information on important European initiatives, including
paediatrics, advanced therapies, the technology platform,
pharmacogenomics, pharmacovigilance, risk management planning and
more."

As part of its efforts to continue the evolution of the
pharmaceutical arena within the European Union (EU), the European
Medicines Agency (EMEA) has developed a long-term strategy to improve
the regulatory environment for medicinal products and to stimulate
innovation and research and development in the EU, which will be
examined in the session entitled, "The European Medicines Agency
Roadmap to 2010: Preparing the Ground for the Future."

In addition, two special events will take place. The Japanese
Regulatory Meeting will bring together representatives from the
University of Tokyo and the Pharmaceuticals and Medical Devices Agency
to discuss global drug development in Japan, including "PMDA
Challenges for Global Drug Development" and "Recent Examples of
Approved Drugs Based on Data from Multi-Regional Clinical Trials."
Also, the Austrian Satellite Meeting, moderated by Dr. Christa
Wirthumer-Hoche, will feature a discussion about the latest
initiatives being undertaken by the Austrian Agency for Health and
Food Safety. It is free to all registered attendees. For more
information or to reserve your seat, please contact:
euromeeting2007@diaeurope.org or visit www.diaeurope.org.

The Plenary Session on Monday, March 26 will feature keynote
speakers Andrew Witty, President, Pharmaceuticals Europe,
GlaxoSmithKline, UK, and Georgette Lalis, Director of the Directorate
for Consumer Goods, European Commission, DG Enterprise and Industry,
EU. Other featured speakers will include representatives from the
EMEA; European Commission; FDA; Japanese PMDA; Danish Medicines
Agency; AGES PharmMed; EFPIA, Belgium; AESGP, Belgium; and European
Generic Medicines Association, Belgium.

To register, visit www.diaeurope.org or contact the EuroMeeting
team at euromeeting2007@diaeurope.org or +41 61 225 51 51.

About The Drug Information Association (DIA)

The DIA serves more than 18,000 professionals in the
biotechnology, pharmaceutical and regulatory industries worldwide.
Through its domestic and international meetings, training courses,
workshops and webinars, DIA provides a neutral global forum for the
exchange of information critical to the advancement of the drug
discovery and lifecycle management processes. Headquartered in
Horsham, Pa., USA, and with offices in Basel, Switzerland and Tokyo,
Japan, the Association is led by its volunteer-based board of
directors and executive management team. For more information, visit
www.diahome.org or call +1-215-442-6100. In Europe, please call +41 61
225 51 51.